Physician profile
Michael G Risbano
NPI 1457307589
$34,230.15
in general payments reported to CMS, 2019-2025
23 companies · $17K in 2025
The $17K reported for 2025 was more than what 97% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $259 · 2021: $568 · 2022: $2,093 · 2023: $329 · 2024: $14K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $4,651 · Food and Beverage: $2,836 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,265.00 |
| Travel and Lodging | $4,651.03 |
| Food and Beverage | $2,835.76 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17,804.40 | 2024-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $6,211.41 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Chiesi USA, INC. | $4,736.82 | 2025 | |
| United Therapeutics Corporation | $1,799.92 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Gilead Sciences, INC. | $1,730.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $478.24 | 2019-2025 | |
| Amgen INC. | $341.34 | 2020-2025 | Repatha, Repatha |
| Liquidia Technologies, INC. | $226.12 | 2025 | Yutrepia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.42 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $156.33 | 2025 | Ekosonic |
| Amarin Pharma, INC. | $123.81 | 2020-2021 | |
| Sandoz INC. | $76.11 | 2024-2025 | Treprostinil |
| Lexicon Pharmaceuticals, INC. | $67.79 | 2023-2024 | Inpefa |
| Janssen Research & Development, LLC | $60.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $57.42 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.59 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $35.10 | 2022-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.78 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.38 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $20.14 | 2025 | Evkeeza |
| Cardiovascular Systems INC. | $14.68 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Risbano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.